Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Shares Outstanding (2016 - 2025)

UroGen Pharma (URGN) has disclosed Shares Outstanding for 10 consecutive years, with $48.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding rose 14.49% year-over-year to $48.4 million, compared with a TTM value of $48.4 million through Dec 2025, up 14.49%, and an annual FY2025 reading of $48.4 million, up 14.49% over the prior year.
  • Shares Outstanding was $48.4 million for Q4 2025 at UroGen Pharma, up from $46.8 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $48.4 million in Q4 2025 and bottomed at $22.3 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $32.0 million, with a median of $27.2 million recorded in 2023.
  • The sharpest move saw Shares Outstanding increased 1.33% in 2021, then skyrocketed 75.2% in 2024.
  • Year by year, Shares Outstanding stood at $22.5 million in 2021, then grew by 2.97% to $23.1 million in 2022, then skyrocketed by 40.47% to $32.5 million in 2023, then increased by 29.98% to $42.2 million in 2024, then grew by 14.49% to $48.4 million in 2025.
  • Business Quant data shows Shares Outstanding for URGN at $48.4 million in Q4 2025, $46.8 million in Q3 2025, and $46.2 million in Q2 2025.